Amyotrophic Lateral Sclerosis (ALS) Treatment

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons in the brain and spinal cord. This comprehensive treatment guide covers disease-modifying therapies, symptomatic management, multidisciplinary care approaches, and emerging treatments for ALS and related motor neuron.

Overview

ALS results in progressive muscle weakness, paralysis, and ultimately respiratory failure, typically within 2-5 years of symptom onset^{1Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the literature2013 · NeuroepidemiologyOpen reference}. Approximately 10% of cases are familial, with C9orf72, SOD1, FUS, and TARDBP being the most common genetic causes^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}. The remaining 90% are sporadic, with complex multifactorial etiology involving glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, and impaired RNA metabolism^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}.

Disease-Modifying Therapies

FDA-Approved Treatments

Riluzole (Rilutek) Riluzole, approved in 1995, remains the cornerstone of disease-modifying therapy for ALS^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}. The drug acts primarily by inhibiting glutamate release, reducing excitatory neurotransmission, and modulating sodium channels^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}. Clinical trials demonstrated a 2-3 month survival benefit, with more pronounced effects in patients with bulbar-onset disease^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}. The standard dose is 50 mg twice daily, with monitoring of liver function due to potential hepatotoxicity^{7FDA. Rilutek Prescribing Information2019Open reference}. Common side effects include dizziness, fatigue, and nausea^{8A controlled trial of riluzole in amyotrophic lateral sclerosis1994 · N Engl J MedOpen reference}.

Edaravone (Radicava) Edaravone, approved in 2017, is a free radical scavenger that reduces oxidative stress, a key pathological mechanism in ALS^{9Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (ALS)2006 · J Neurol Sci · PMID 16631761Open reference}. The approval was based on the MCI186-19 trial showing reduced functional decline measured by ALSFRS-R score compared to placebo^{10Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial2017 · Lancet Neurol · PMID 28501369Open reference}. Treatment involves intravenous infusion for 14 days followed by 14-day drug-free periods^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}0. Post-marketing studies suggest greater benefit in patients with earlier disease stage and better baseline function^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}1. Common adverse effects include bruising, gait disturbance, and headache^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}2.

AMX0035 (Relyvrio) AMX0035 (sodium phenylbutyrate/taurursodiol), approved in 2022, targets mitochondrial dysfunction and endoplasmic reticulum stress, two interconnected pathways in ALS pathogenesis^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}3. The CENTAUR trial demonstrated significant survival benefit (median 9.7 months) and slower functional decline compared to placebo^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}4. The drug is administered orally as a powder mixed with water, with dosing initiated at 1 packet daily for 3 weeks, then increased to 1 packet twice daily^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}5. Common side effects include diarrhea, abdominal pain, and nausea^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}6.

Tofersen (Qalsody) Tofersen, approved in 2023, is an antisense oligonucleotide (ASO) therapy specifically targeting SOD1 gene mutations, which account for approximately 2% of all ALS cases^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}7. The VALOR trial demonstrated significant reduction in SOD1 protein and neurofilament light chain (NfL) levels, with a trend toward clinical benefit in the open-label extension^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}8. Treatment involves intrathecal administration every 28 days, requiring lumbar puncture or implanted intrathecal port^{2State of play in ALS genetics2014 · Nat Rev Neurol · PMID 25113687Open reference}9. Patients must have confirmed SOD1 mutation to receive treatment^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}0.

Off-Label and Repurposed Agents

Lamotrigine This anti-epileptic drug blocks voltage-gated sodium channels and reduces glutamate release^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}1. Retrospective analyses suggest possible modest benefit in bulbar-onset ALS, though prospective trials are lacking^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}2.

Minocycline This antibiotic with anti-inflammatory properties showed promise in preclinical models but failed to demonstrate benefit in Phase III trials^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}3.

Lithium While early studies suggested neuroprotective effects, a large randomized trial (LIT-ALS) did not confirm clinical benefit^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}4.

Symptomatic Management

Muscle Cramps and Spasticity

Mexiletine This sodium channel blocker effectively reduces muscle cramps in ALS, with the phase II BEST-I trial demonstrating significant reduction in cramp frequency and severity^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}5. Starting dose is 150 mg daily, titrated to 300 mg twice daily as tolerated^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}6. Cardiac monitoring is recommended due to potential QT prolongation^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}7.

Baclofen and Tizanidine These GABA-B and alpha-2 adrenergic agonists respectively reduce spasticity^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}8. Baclofen dosing starts at 5-10 mg three times daily, titrating to 30-40 mg three times daily^{3Amyotrophic lateral sclerosis2017 · Nat Rev Dis Primers · PMID 28980624Open reference}9. Side effects include sedation, dizziness, and weakness^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}0. Tizanidine is an alternative with similar efficacy and side effect profile^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}1.

Quinine Historically used for cramps, quinine is no longer recommended due to cardiac toxicity concerns and modest efficacy^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}2.

Dysphagia and Nutrition

Nutritional Intervention Early nutritional assessment is critical as weight loss and malnutrition are associated with faster disease progression^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}3. Percutaneous endoscopic gastrostomy (PEG) tube placement is recommended when weight loss exceeds 10% of body weight or when dysphagia compromises oral intake^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}4. Studies show PEG placement is safe in ALS when performed before significant respiratory compromise (FVC < 50%)^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}5.

Feeding Strategies

• Thickened liquids and modified textures for safety

• High-calorie supplements to meet metabolic demands

• Regular dietician consultation for individualized plans^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}6

Respiratory Management

Non-Invasive Ventilation (NIV) NIV improves survival and quality of life in ALS patients with respiratory weakness^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}7. Initiation is recommended when symptomatically indicated or when FVC falls below 50% predicted^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}8. Bi-level positive airway pressure (BiPAP) is the standard modality, with initial settings of IPAP 12-14 cm H2O and EPAP 4-6 cm H2O^{4Dose-ranging study of riluzole in amyotrophic lateral sclerosis1996 · Lancet · PMID 8622708Open reference}9.

Cough Assist Devices Mechanical insufflation-exsufflation devices help clear secretions and prevent pulmonary complications^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}0. Use is recommended when peak cough flow falls below 270 L/min^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}1.

Invasive Ventilation Tracheostomy with long-term mechanical ventilation is an option for patients who desire maximal life extension, though quality of life considerations must be addressed in decision-making^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}2.

Sialorrhea Management

Botulinum Toxin Injections Botulinum toxin (Botox or Xeomin) injected into salivary glands (parotid and submandibular) effectively reduces drooling^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}3. Effects last 3-4 months, with typical dosing of 20-30 units per gland^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}4.

Anticholinergic Medications Scopolamine patches, glycopyrrolate, and amitriptyline can reduce saliva production but may cause cognitive side effects in elderly patients^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}5.

Pseudobulbar Affect

Dextromethorphan/Quinidine (Nuedexta) This combination is FDA-approved for pseudobulbar affect (PBA) in ALS, significantly reducing episodes of uncontrolled crying or laughing^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}6. Dosing is 20/10 mg twice daily^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}7. Contraindicated in patients taking MAO inhibitors or with certain cardiac conditions^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}8.

Multidisciplinary Care

Clinic Model

Multidisciplinary ALS clinics, endorsed by the American Academy of Neurology and European guidelines, improve survival and quality of life compared to standard care^{5A review of the pharmacological of action of riluzole in treating amyotrophic lateral sclerosis2012 · Am J Alzheimers Dis Other Demen · PMID 22430658Open reference}9. Core team members include:

Frequency of Follow-Up

• Every 3 months for ambulatory patients

• Every 1-2 months for patients with rapid progression

• As needed for acute symptom management^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}0

Emerging Therapies

Gene Therapy Approaches

C9orf72-Targeting Therapies ASOs and small molecules targeting the C9orf72 hexanucleotide repeat expansion, the most common genetic cause of ALS, are in various trial stages^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}1. Waves Therapeutics has an ASO (WTX-114) in Phase I/II for C9orf72-associated ALS^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}2.

FUS-Targeting Therapies FUS mutations cause approximately 5% of familial ALS. ASO therapies targeting FUS are in preclinical and early clinical development^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}3.

Stem Cell Therapies

Neural Stem Cell Transplantation Phase I/II trials (NCT01348451, NCT01640067) have evaluated neural stem cell delivery to the spinal cord, showing preliminary safety and potential biological effects^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}4. Mesenchymal stem cells with neurotrophic factor secretion are also under investigation^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}5.

Neuroprotective Strategies

Nuedexta Beyond PBA Post-hoc analyses suggest potential neuroprotective effects of the dextromethorphan component through sigma-1 receptor agonism^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}6.

Retigabine This potassium channel opener was investigated for neuroprotection but the phase II/III SIERRA trial was discontinued due to lack of efficacy^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}7.

Repurposed Drugs

Celecoxib The COXPEM study is evaluating celecoxib for neuroinflammation modulation in ALS^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}8.

Ibudilast This PDE4/MIF inhibitor has completed Phase II trials for ALS (NCT03959592). It reduces neuroinflammation through dual mechanism: PDE4 inhibition increases cAMP to suppress microglial activation, while MIF antagonism blocks a pro-inflammatory cytokine pathway. Clinical trials showed favorable safety with trends toward slower functional decline.

Masitinib This tyrosine kinase inhibitor targeting mast cells showed promise in a phase III trial, with ongoing regulatory discussions^{6Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)2012 · Cochrane Database Syst Rev · PMID 22419278Open reference}9.

Clinical Trial Considerations

Active Trials

Trial Eligibility

Common inclusion criteria:

• Age 18-80 years

• Definite or probable ALS per El Escorial or Awaji criteria

• Disease duration < 24 months

• FVC > 50% predicted

• Able to provide informed consent

Trial Phases

1. Phase I: Safety and dosing (healthy volunteers or small ALS cohort)

2. Phase II: Efficacy signals and dose-ranging

3. Phase III: Large-scale confirmation of benefit

4. Phase IV: Post-marketing surveillance

Palliative Care Integration

Timing of Palliative Care Referral

Early integration of palliative care improves quality of life and may extend survival^{7FDA. Rilutek Prescribing Information2019Open reference}0. Referral is recommended:

• At diagnosis for advance care planning

• When functional decline accelerates

• When respiratory symptoms emerge

• For psychosocial support needs

Symptom Management in Palliative Phase

Pain Management

• Neuropathic pain: gabapentin, pregabalin, duloxetine

• Musculoskeletal pain: physical therapy, acetaminophen, NSAIDs

• Incident pain during transfers: preemptive analgesia^{7FDA. Rilutek Prescribing Information2019Open reference}1

Dyspnea Management

• Opioids: morphine 2.5-5 mg every 4 hours as needed

• Benzodiazepines for anxiety: lorazepam 0.5-1 mg as needed

• Oxygen for hypoxemia^{7FDA. Rilutek Prescribing Information2019Open reference}2

Psychosocial Support

• Caregiver education and respite

• Bereavement support

• Legacy projects and life review^{7FDA. Rilutek Prescribing Information2019Open reference}3

Advance Care Planning

Key discussions:

• Artificial nutrition and hydration preferences

• Respiratory support preferences (NIV vs. invasive ventilation)

• Code status

• Hospice enrollment timing^{7FDA. Rilutek Prescribing Information2019Open reference}4

Treatment Algorithm

flowchart TD
 A["ALS Diagnosis"]  -->  B{"Confirm Genetic Subtype"}
 B  -->|"SOD1+"| C["Tofersen + Standard Care"]
 B  -->|"SOD1-"| D["Standard Care"]
 C  -->  E["Riluzole + Edaravone + AMX0035"]
 D  -->  E
 E  -->  F["Multidisciplinary Clinic"]
 F  -->  G{"Symptom Assessment"}
 G  -->|"Cramps"| H["Mexiletine/Baclofen"]
 G  -->|"Spasticity"| I["Baclofen/Tizanidine"]
 G  -->|"Dysphagia"| J["Nutrition Assessment/PEG"]
 G  -->|"Respiratory"| K["NIV/Cough Assist"]
 G  -->|"Sialorrhea"| L["Botox/Anticholinergics"]
 G  -->|"PBA"| M["Nuedexta"]
 H  -->  N["Regular Follow-Up"]
 I  -->  N
 J  -->  N
 K  -->  N
 L  -->  N
 M  -->  N
 N  -->  O{"Progression"}
 O  -->|"Stable"| F
 O  -->|"Advanced"| P["Palliative Care"]
 P  -->  Q["Symptom Management"]
 Q  -->  R["Goals of Care Discussion"]

Prognosis and Outcomes

Survival Factors

Expected Outcomes with Treatment

• Untreated median survival: 2-4 years

• With riluzole: 3-5 months median extension

• With multidisciplinary care: 7-12 months median extension

• With full support: Varied, some live >10 years^{7FDA. Rilutek Prescribing Information2019Open reference}5

See Also

• Cell Types Overview

• Gene Overview

• Disease Overview

External Links

• ALS Association

• MDA ALS Division

• CureALS

• ClinicalTrials.gov - ALS